133 related articles for article (PubMed ID: 34941047)
21. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
22. Comment on: Irinotecan dose schedule for the treatment of Ewing sarcoma-protracted/metronomic schedule-wording matters!
André N
Pediatr Blood Cancer; 2023 Apr; 70(4):e30124. PubMed ID: 36495251
[No Abstract] [Full Text] [Related]
23. Impact of locus of care on outcomes in adolescents and young adults with osteosarcoma and Ewing sarcoma treated at pediatric versus adult cancer centers: An IMPACT cohort study.
Mortazavi M; Baxter NN; Gupta S; Gupta AA; Lau C; Nagamuthu C; Nathan PC
Pediatr Blood Cancer; 2022 Apr; 69(4):e29458. PubMed ID: 35029312
[TBL] [Abstract][Full Text] [Related]
24. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
25. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Chaber R; Pogorzala M; Wyrobek E; Polczyńska K; Rogowska E; Rodriguez-Galindo C; Wozniak W
Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
[TBL] [Abstract][Full Text] [Related]
26. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
27. Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Anderson P; Ghisoli M; Crompton BD; Klega KS; Wexler LH; Slotkin EK; Stanbery L; Manning L; Wallraven G; Manley M; Horvath S; Bognar E; Nemunaitis J
Clin Cancer Res; 2023 May; 29(9):1689-1697. PubMed ID: 36780200
[TBL] [Abstract][Full Text] [Related]
28. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
Palmerini E; Jones RL; Setola E; Picci P; Marchesi E; Luksch R; Grignani G; Cesari M; Longhi A; Abate ME; Paioli A; Szucs Z; D'ambrosio L; Scotlandi K; Fagioli F; Asaftei S; Ferrari S
Acta Oncol; 2018 Jul; 57(7):958-964. PubMed ID: 29533113
[TBL] [Abstract][Full Text] [Related]
29. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
[TBL] [Abstract][Full Text] [Related]
30. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.
Shulman DS; Merriam P; Choy E; Guenther LM; Cavanaugh KL; Kao PC; Posner A; Bhushan K; Fairchild G; Barker E; Klega K; Stegmaier K; Crompton BD; London WB; DuBois SG
Cancer Med; 2023 Jul; 12(14):15207-15216. PubMed ID: 37306107
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy and survival of 92 cases of Ewing's sarcoma family of tumor initially treated with multidisciplinary therapy].
Peng RJ; Sun XF; Xiang XJ; Zhen ZJ; Ling JY; Tong GL; Xia Y; Xu GC; Jiang WQ
Ai Zheng; 2009 Dec; 28(12):1304-9. PubMed ID: 19958626
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.
Lu E; Ryan CW; Bassale S; Lim JY; Davis LE
Oncologist; 2020 Feb; 25(2):150-155. PubMed ID: 32043790
[TBL] [Abstract][Full Text] [Related]
33. Multimodal therapy for children and adolescents with Ewing sarcoma: results of the First National Chilean Trial (1986-1991).
Villarroel M; Tordecilla J; Salgado C; Luo X; Messen S; Rayo Y; Zolezzi P; Rojas J
Med Pediatr Oncol; 1997 Sep; 29(3):190-6. PubMed ID: 9212843
[TBL] [Abstract][Full Text] [Related]
34. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
[TBL] [Abstract][Full Text] [Related]
35. High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with first recurrence of Ewing sarcoma.
Haveman LM; van Ewijk R; van Dalen EC; Breunis WB; Kremer LC; van den Berg H; Dirksen U; Merks JH
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011406. PubMed ID: 34472084
[TBL] [Abstract][Full Text] [Related]
36. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma.
Takenaka S; Naka N; Obata H; Joyama S; Hamada K; Imura Y; Kakunaga S; Aoki Y; Ueda T; Araki N; Yoshikawa H
Jpn J Clin Oncol; 2016 Jun; 46(6):522-8. PubMed ID: 27008849
[TBL] [Abstract][Full Text] [Related]
38. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
[TBL] [Abstract][Full Text] [Related]
39. Primary cutaneous and subcutaneous Ewing sarcoma.
Di Giannatale A; Frezza AM; Le Deley MC; Marec-Bérard P; Benson C; Blay JY; Bui B; Judson I; Oberlin O; Whelan J; Gaspar N
Pediatr Blood Cancer; 2015 Sep; 62(9):1555-61. PubMed ID: 25894676
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
Paioli A; Luksch R; Fagioli F; Tamburini A; Cesari M; Palmerini E; Abate ME; Marchesi E; Balladelli A; Pratelli L; Ferrari S
J Chemother; 2014 Feb; 26(1):49-56. PubMed ID: 24091100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
